This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Rare Neurological Disease Treatment Market

Market Insights on Rare Neurological Disease Treatment covering sales outlook, demand forecast & up-to-date key trends

Rare Neurological Disease Treatment Market by Indication (Alzheimer's Disease, Narcolepsy, Multiple Sclerosis, Amyotrophic Lateral Sclerosis), Drug Type (Biologics, Organic Compounds), Mode of Administration, Distribution Channel & Region - Forecast to 2017-2026

Introduction

Majority of rare diseases at present have none or little effective procedures of diagnosis & treatment, which can be partly attributed to absence of funding toward researches on rare disease pathogenesis and lack of representative patients. Rare neurological disease are among major types of rare diseases with ineffective diagnoses and treatment options. According to WHO, 1 in 10 individuals are expected to be diagnosed with rare neurological disorder in their lifetime. Brain diseases are considered to be one of the major determinants of the neurological disease prevalence worldwide, with early intervention being the only key to prevent or curtail long-term morbidity and relevant healthcare costs.

However, diagnosis of rare neurological diseases entails several barricades including lack of intelligence and awareness about such diseases within the common medical community. This has further resulted into delayed diagnosis, and sometimes misdiagnosis, as highlighted in the book about rare diseases compiled by European Organization for Rare Diseases (EURORDIS), co-funded by European Commission. According to the publication, patients suffering from rare neurological diseases experience challenges in accessing treatment services on the coattails of lack of referral.

Spreading awareness about these diseases along with increasing their visibility are key initiatives taken by various governments worldwide for speeding up diagnostic processes and provide affected families with access to proper counselling and treatment options.

A recently published report of Future Market Insights foresees the global rare neurological disease treatment market to record a spectacular growth between the period 2017 and 2026. Revenues from treatment of rare neurological disorders worldwide are poised to surpass US$ 12,000 Mn by 2026-end.

Customize this Report

Let us know your requirement to get
100% FREE customization

North America to Remain Largest Revenue Contributor to the Market

In North America, rare neurological conditions are considered to a major healthcare concern, although fewer individuals are currently affected by the disease. Complexity of these diseases, along with their inadequacy in treatment options have led to disproportionate share of spending in healthcare. Drug companies in North America are conducting robust researches in rare diseases, however they face difficulties related to cost of treatment development related to small or geographically dispersed populations.

Rare Neurological Disease Treatment Market Download Report Brochure

Government and healthcare institutes in North America are therefore collaborating to develop a robust research network, in order to facilitate data sharing, enrollment in trials & studies, and advancement in rare diseases. This will further influence the rare neurological disease treatment market in North America. The report estimates North America to remain the largest revenue contributor to the market.

Discrepancies in R&D Funding for Rare Neurological Disease Linked with Shortage in Healthcare Provision

Management of rare neurological diseases and provision of effective therapies represent an economic and social burden on several nations. Treatment options for patients affected with rare neurological conditions continue to be limited. Discrepancies in funding for R&D associated with treatment & prevention of these diseases is mainly linked with shortfall in the healthcare provision that reflects both shortage of material sources and suboptimal training exercises of clinicians apropos brain disorders.

Although there have been notable advancements in treatment of rare neurological diseases, these are not completely curative. Governments across the globe are therefore making significant improvements in their healthcare systems to render their management to be multidisciplinary, holistic, and to include supportive and palliative care. Establishing centers of expertise, which specialize in diagnosis, treatment & care of patients affected from rare neurological diseases, is a key focus area for most of the developed and developing countries across the globe.

Key players fuelling growth of the global rare neurological disease treatment market, as identified by the report, include Pfizer Inc., Allergan Plc, Novartis AG, Bayer Aktiengesellschaft, Medtronic Plc, Sanofi, Johnson & Johnson, and Teva Pharmaceutical Industries Limited.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Automotive performance tuning and engine remapping services Market

By Vehicle Type:

  • Passenger cars
  • Light commercial Vehicles
  • Heavy Commercial Vehicles

By Fuel Type:

By Tuning stage:

  • Stage 1
  • Stage 2
  • Stage 3

By Tuning Method:

  • OBD Ports
  • Bench Tuning

By Application:

  • Racing
  • Fuel Economizing
  • Performance tuning

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa
Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Frequently Asked Questions

The rare neurological disease treatment market is predicted to grow at an 8.7% CAGR through 2032.

North America rare neurological disease treatment market holds the highest revenue potential.

The rare neurological disease treatment market is expected to surpass US$ 19.795.14 Mn by 2032.

The rare neurological disease treatment market size is anticipated to be over US$ 8595.34 Mn in 2022.

Table of Content

1. Global Economic Outlook

2. Global Market - Executive Summary

3. Global Market Overview

    3.1. Introduction

        3.1.1. Global Market Taxonomy

        3.1.2. Global Market Definition

    3.2. Global Market Size (US$ Mn) and Forecast, 2012-2026

        3.2.1. Global Market Y-o-Y Growth

    3.3. Global Market Dynamics

    3.4. Supply Chain

    3.5. Cost Structure

    3.6. USA, EU & Japan Orphan Designations per Year & Cumulative (1983 – 2016)

    3.7. Worldwide Top 20 Orphan Drug Manufacturers (2016 – 2022)

    3.8. Wheel of Fortune

    3.9. Rare Disease Key Regulations

        3.9.1. Rare Disease Key Regulations: North America

        3.9.2. Rare Disease Key Regulations: Latin America

        3.9.3. Rare Disease Key Regulations: Europe

        3.9.4. Rare Disease Key Regulations: Asia Pacific

        3.9.5. Rare Disease Key Regulations: Middle East & Africa

    3.10. Forecast Scenario

    3.11. PEST Analysis

    3.12. Porte's Five Forces Analysis

    3.13. Market Positioning and Behavioral Assessment

    3.14. Investment Feasibility Assessment

    3.15. Competitor Market Footprint Matrix

    3.16. Key Participants Market Presence (Intensity Map) By Region

4. Global Market Analysis and Forecast 2012-2026 

    4.1. Global Market Size and Forecast By Indication, 2012-2026

        4.1.1. Alzheimer’s Disease Market Size and Forecast, 2012-2026

            4.1.1.1. Revenue (US$ Mn) Comparison, By Region

            4.1.1.2. Market Share Comparison, By Region

            4.1.1.3. Y-o-Y growth Comparison, By Region

        4.1.2. Narcolepsy Market Size and Forecast, 2012-2026

            4.1.2.1. Revenue (US$ Mn) Comparison, By Region

            4.1.2.2. Market Share Comparison, By Region

            4.1.2.3. Y-o-Y growth Comparison, By Region

        4.1.3. Multiple Sclerosis Market Size and Forecast, 2012-2026

            4.1.3.1. Revenue (US$ Mn) Comparison, By Region

            4.1.3.2. Market Share Comparison, By Region

            4.1.3.3. Y-o-Y growth Comparison, By Region

        4.1.4. Amyotrophic Lateral Sclerosis Market Size and Forecast, 2012-2026

            4.1.4.1. Revenue (US$ Mn) Comparison, By Region

            4.1.4.2. Market Share Comparison, By Region

            4.1.4.3. Y-o-Y growth Comparison, By Region

        4.1.5. Other Indications Market Size and Forecast, 2012-2026

            4.1.5.1. Revenue (US$ Mn) Comparison, By Region

            4.1.5.2. Market Share Comparison, By Region

            4.1.5.3. Y-o-Y growth Comparison, By Region

    4.2. Global Market Size and Forecast By Drug Type, 2012-2026

        4.2.1. Biologics Market Size and Forecast, 2012-2026

            4.2.1.1. Revenue (US$ Mn) Comparison, By Region

            4.2.1.2. Market Share Comparison, By Region

            4.2.1.3. Y-o-Y growth Comparison, By Region

        4.2.2. Organic Compounds Market Size and Forecast, 2012-2026

            4.2.2.1. Revenue (US$ Mn) Comparison, By Region

            4.2.2.2. Market Share Comparison, By Region

            4.2.2.3. Y-o-Y growth Comparison, By Region

    4.3. Global Market Size and Forecast By Mode of Administration, 2012-2026

        4.3.1. Injectable Market Size and Forecast, 2012-2026

            4.3.1.1. Revenue (US$ Mn) Comparison, By Region

            4.3.1.2. Market Share Comparison, By Region

            4.3.1.3. Y-o-Y growth Comparison, By Region

        4.3.2. Oral Market Size and Forecast, 2012-2026

            4.3.2.1. Revenue (US$ Mn) Comparison, By Region

            4.3.2.2. Market Share Comparison, By Region

            4.3.2.3. Y-o-Y growth Comparison, By Region

        4.3.3. Others Market Size and Forecast, 2012-2026

            4.3.3.1. Revenue (US$ Mn) Comparison, By Region

            4.3.3.2. Market Share Comparison, By Region

            4.3.3.3. Y-o-Y growth Comparison, By Region

    4.4. Global Market Size and Forecast By Distribution Channel, 2012-2026

        4.4.1. Hospital Pharmacies Market Size and Forecast, 2012-2026

            4.4.1.1. Revenue (US$ Mn) Comparison, By Region

            4.4.1.2. Market Share Comparison, By Region

            4.4.1.3. Y-o-Y growth Comparison, By Region

        4.4.2. Retail Pharmacies Market Size and Forecast, 2012-2026

            4.4.2.1. Revenue (US$ Mn) Comparison, By Region

            4.4.2.2. Market Share Comparison, By Region

            4.4.2.3. Y-o-Y growth Comparison, By Region

        4.4.3. Online Pharmacies Market Size and Forecast, 2012-2026

            4.4.3.1. Revenue (US$ Mn) Comparison, By Region

            4.4.3.2. Market Share Comparison, By Region

            4.4.3.3. Y-o-Y growth Comparison, By Region

5. North America Market Size and Forecast, 2012-2026

    5.1. North America Outlook 

    5.2. North America Parent Market Outlook 

    5.3. North America Target Market Outlook 

    5.4. Revenue (US$ Mn) Comparison, By Country 

        5.4.1. US Market Size and Forecast (US$ Mn), 2012-2026

        5.4.2. Canada Market Size and Forecast (US$ Mn), 2012-2026

    5.5. Revenue (US$ Mn) Comparison, By Indication 

    5.6. Revenue (US$ Mn) Comparison, By Drug Type 

    5.7. Revenue (US$ Mn) Comparison, By Mode of Administration 

    5.8. Revenue (US$ Mn) Comparison, By Distribution Channel 

6. Latin America Market Size and Forecast, 2012-2026

    6.1. Latin America Outlook 

    6.2. Latin America Parent Market Outlook 

    6.3. Latin America Target Market Outlook 

    6.4. Revenue (US$ Mn) Comparison, By Country 

        6.4.1. Brazil Market Size and Forecast (US$ Mn), 2012-2026

        6.4.2. Mexico Market Size and Forecast (US$ Mn), 2012-2026

        6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2012-2026

    6.5. Revenue (US$ Mn) Comparison, By Indication 

    6.6. Revenue (US$ Mn) Comparison, By Drug Type 

    6.7. Revenue (US$ Mn) Comparison, By Mode of Administration 

    6.8. Revenue (US$ Mn) Comparison, By Distribution Channel 

7. Europe Market Size and Forecast, 2012-2026

    7.1. Europe Outlook 

    7.2. Europe Parent Market Outlook 

    7.3. Europe Target Market Outlook 

    7.4. Revenue (US$ Mn) Comparison, By Country 

        7.4.1. Germany Market Size and Forecast (US$ Mn), 2012-2026

        7.4.2. UK Market Size and Forecast (US$ Mn), 2012-2026

        7.4.3. France Market Size and Forecast (US$ Mn), 2012-2026

        7.4.4. Spain Market Size and Forecast (US$ Mn), 2012-2026

        7.4.5. Italy Market Size and Forecast (US$ Mn), 2012-2026

        7.4.6. Rest of Europe Market Size and Forecast (US$ Mn), 2012-2026

    7.5. Revenue (US$ Mn) Comparison, By Indication 

    7.6. Revenue (US$ Mn) Comparison, By Drug Type 

    7.7. Revenue (US$ Mn) Comparison, By Mode of Administration 

    7.8. Revenue (US$ Mn) Comparison, By Distribution Channel 

8. Japan Market Size and Forecast, 2012-2026

    8.1. Japan Outlook 

    8.2. Japan Parent Market Outlook 

    8.3. Japan Target Market Outlook 

    8.4. Japan  Market Size and Forecast (US$ Mn), 2012-2026 

    8.5. Revenue (US$ Mn) Comparison, By Indication 

    8.6. Revenue (US$ Mn) Comparison, By Drug Type 

    8.7. Revenue (US$ Mn) Comparison, By Mode of Administration 

    8.8. Revenue (US$ Mn) Comparison, By Distribution Channel 

9. APEJ Market Size and Forecast, 2012-2026

    9.1. APEJ Outlook 

    9.2. APEJ Parent Market Outlook 

    9.3. APEJ Target Market Outlook 

    9.4. Revenue (US$ Mn) Comparison, By Country 

        9.4.1. China Market Size and Forecast (US$ Mn), 2012-2026

        9.4.2. India Market Size and Forecast (US$ Mn), 2012-2026

        9.4.3. Thailand Market Size and Forecast (US$ Mn), 2012-2026

        9.4.4. Singapore Market Size and Forecast (US$ Mn), 2012-2026

        9.4.5. Australia Market Size and Forecast (US$ Mn), 2012-2026

        9.4.6. Rest of APEJ Market Size and Forecast (US$ Mn), 2012-2026

    9.5. Revenue (US$ Mn) Comparison, By Indication 

    9.6. Revenue (US$ Mn) Comparison, By Drug Type 

    9.7. Revenue (US$ Mn) Comparison, By Mode of Administration 

    9.8. Revenue (US$ Mn) Comparison, By Distribution Channel 

10. MEA Market Size and Forecast, 2012-2026

    10.1. MEA Outlook 

    10.2. MEA Parent Market Outlook 

    10.3. MEA Target Market Outlook 

    10.4. Revenue (US$ Mn) Comparison, By Country 

        10.4.1. GCC Countries Market Size and Forecast (US$ Mn), 2012-2026

        10.4.2. South Africa Market Size and Forecast (US$ Mn), 2012-2026

        10.4.3. Nigeria Market Size and Forecast (US$ Mn), 2012-2026

        10.4.4. Rest of MEA Market Size and Forecast (US$ Mn), 2012-2026

    10.5. Revenue (US$ Mn) Comparison, By Indication 

    10.6. Revenue (US$ Mn) Comparison, By Drug Type 

    10.7. Revenue (US$ Mn) Comparison, By Mode of Administration 

    10.8. Revenue (US$ Mn) Comparison, By Distribution Channel 

11. Global Market Company Share, Competition Landscape and Company Profiles

    11.1. Global Market Company Share Analysis

    11.2. Global Market Competition Landscape

    11.3. Global Market Company Profiles

        11.3.1. Pfizer Inc.

        11.3.2. Allergan Plc

        11.3.3. Novartis AG

        11.3.4. Bayer Aktiengesellschaft

        11.3.5. Medtronic Plc

        11.3.6. Sanofi

        11.3.7. Johnson & Johnson

        11.3.8. Teva Pharmaceutical Industries Limited

        11.3.9. Jazz Pharmaceuticals

        11.3.10. EMD Serono, Inc.

12. Key Takeaways

13. Research Methodology

14. Disclaimer

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

TABLE 1 Global Market Value (US$ Mn), 2012-2017

TABLE 2 Global Market Value (US$ Mn), 2018-2026

TABLE 3 Global Market Value (US$ Mn) and Y-o-Y, 2017-2026

TABLE 4 Global Alzheimer’s Disease Segment Value (US$ Mn), By Region 2012-2017

TABLE 5 Global Alzheimer’s Disease Segment Value (US$ Mn), By Region 2018-2026

TABLE 6 Global Alzheimer’s Disease Segment Market Share, By Region 2012-2017

TABLE 7 Global Alzheimer’s Disease Segment Market Share, By Region 2018-2026

TABLE 8 Global Alzheimer’s Disease Segment Y-o-Y, By Region 2017-2026

TABLE 9 Global Narcolepsy Segment Value (US$ Mn), By Region 2012-2017

TABLE 10 Global Narcolepsy Segment Value (US$ Mn), By Region 2018-2026

TABLE 11 Global Narcolepsy Segment Market Share, By Region 2012-2017

TABLE 12 Global Narcolepsy Segment Market Share, By Region 2018-2026

TABLE 13 Global Narcolepsy Segment Y-o-Y, By Region 2017-2026

TABLE 14 Global Multiple Sclerosis Segment Value (US$ Mn), By Region 2012-2017

TABLE 15 Global Multiple Sclerosis Segment Value (US$ Mn), By Region 2018-2026

TABLE 16 Global Multiple Sclerosis Segment Market Share, By Region 2012-2017

TABLE 17 Global Multiple Sclerosis Segment Market Share, By Region 2018-2026

TABLE 18 Global Multiple Sclerosis Segment Y-o-Y, By Region 2017-2026

TABLE 19 Global Amyotrophic Lateral Sclerosis Segment Value (US$ Mn), By Region 2012-2017

TABLE 20 Global Amyotrophic Lateral Sclerosis Segment Value (US$ Mn), By Region 2018-2026

TABLE 21 Global Amyotrophic Lateral Sclerosis Segment Market Share, By Region 2012-2017

TABLE 22 Global Amyotrophic Lateral Sclerosis Segment Market Share, By Region 2018-2026

TABLE 23 Global Amyotrophic Lateral Sclerosis Segment Y-o-Y, By Region 2017-2026

TABLE 24 Global Other Indications Segment Value (US$ Mn), By Region 2012-2017

TABLE 25 Global Other Indications Segment Value (US$ Mn), By Region 2018-2026

TABLE 26 Global Other Indications Segment Market Share, By Region 2012-2017

TABLE 27 Global Other Indications Segment Market Share, By Region 2018-2026

TABLE 28 Global Other Indications Segment Y-o-Y, By Region 2017-2026

TABLE 29 Global Biologics Segment Value (US$ Mn), By Region 2012-2017

TABLE 30 Global Biologics Segment Value (US$ Mn), By Region 2018-2026

TABLE 31 Global Biologics Segment Market Share, By Region 2012-2017

TABLE 32 Global Biologics Segment Market Share, By Region 2018-2026

TABLE 33 Global Biologics Segment Y-o-Y, By Region 2017-2026

TABLE 34 Global Organic Compounds Segment Value (US$ Mn), By Region 2012-2017

TABLE 35 Global Organic Compounds Segment Value (US$ Mn), By Region 2018-2026

TABLE 36 Global Organic Compounds Segment Market Share, By Region 2012-2017

TABLE 37 Global Organic Compounds Segment Market Share, By Region 2018-2026

TABLE 38 Global Organic Compounds Segment Y-o-Y, By Region 2017-2026

TABLE 39 Global Injectables Segment Value (US$ Mn), By Region 2012-2017

TABLE 40 Global Injectables Segment Value (US$ Mn), By Region 2018-2026

TABLE 41 Global Injectables Segment Market Share, By Region 2012-2017

TABLE 42 Global Injectables Segment Market Share, By Region 2018-2026

TABLE 43 Global Injectables Segment Y-o-Y, By Region 2017-2026

TABLE 44 Global Oral Segment Value (US$ Mn), By Region 2012-2017

TABLE 45 Global Oral Segment Value (US$ Mn), By Region 2018-2026

TABLE 46 Global Oral Segment Market Share, By Region 2012-2017

TABLE 47 Global Oral Segment Market Share, By Region 2018-2026

TABLE 48 Global Oral Segment Y-o-Y, By Region 2017-2026

TABLE 49 Global Others Segment Value (US$ Mn), By Region 2012-2017

TABLE 50 Global Others Segment Value (US$ Mn), By Region 2018-2026

TABLE 51 Global Others Segment Market Share, By Region 2012-2017

TABLE 52 Global Others Segment Market Share, By Region 2018-2026

TABLE 53 Global Others Segment Y-o-Y, By Region 2017-2026

TABLE 54 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2012-2017

TABLE 55 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2018-2026

TABLE 56 Global Hospital Pharmacies Segment Market Share, By Region 2012-2017

TABLE 57 Global Hospital Pharmacies Segment Market Share, By Region 2018-2026

TABLE 58 Global Hospital Pharmacies Segment Y-o-Y, By Region 2017-2026

TABLE 59 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2012-2017

TABLE 60 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2018-2026

TABLE 61 Global Retail Pharmacies Segment Market Share, By Region 2012-2017

TABLE 62 Global Retail Pharmacies Segment Market Share, By Region 2018-2026

TABLE 63 Global Retail Pharmacies Segment Y-o-Y, By Region 2017-2026

TABLE 64 Global Online Pharmacies Segment Value (US$ Mn), By Region 2012-2017

TABLE 65 Global Online Pharmacies Segment Value (US$ Mn), By Region 2018-2026

TABLE 66 Global Online Pharmacies Segment Market Share, By Region 2012-2017

TABLE 67 Global Online Pharmacies Segment Market Share, By Region 2018-2026

TABLE 68 Global Online Pharmacies Segment Y-o-Y, By Region 2017-2026

TABLE 69 North America Market Value (US$ Mn), By Country 2012-2017

TABLE 70 North America Market Value (US$ Mn), By Country 2018-2026

TABLE 71 North America Market Value (US$ Mn), By Indication 2012-2017

TABLE 72 North America Market Value (US$ Mn), By Indication 2018-2026

TABLE 73 North America Market Value (US$ Mn), By Drug Type 2012-2017

TABLE 74 North America Market Value (US$ Mn), By Drug Type 2018-2026

TABLE 75 North America Market Value (US$ Mn), By Mode of Administration 2012-2017

TABLE 76 North America Market Value (US$ Mn), By Mode of Administration 2018-2026

TABLE 77 North America Market Value (US$ Mn), By Distribution Channel 2012-2017

TABLE 78 North America Market Value (US$ Mn), By Distribution Channel 2018-2026

TABLE 79 Latin America Market Value (US$ Mn), By Country 2012-2017

TABLE 80 Latin America Market Value (US$ Mn), By Country 2018-2026

TABLE 81 Latin America Market Value (US$ Mn), By Indication 2012-2017

TABLE 82 Latin America Market Value (US$ Mn), By Indication 2018-2026

TABLE 83 Latin America Market Value (US$ Mn), By Drug Type 2012-2017

TABLE 84 Latin America Market Value (US$ Mn), By Drug Type 2018-2026

TABLE 85 Latin America Market Value (US$ Mn), By Mode of Administration 2012-2017

TABLE 86 Latin America Market Value (US$ Mn), By Mode of Administration 2018-2026

TABLE 87 Latin America Market Value (US$ Mn), By Distribution Channel 2012-2017

TABLE 88 Latin America Market Value (US$ Mn), By Distribution Channel 2018-2026

TABLE 89 Europe Market Value (US$ Mn), By Country 2012-2017

TABLE 90 Europe Market Value (US$ Mn), By Country 2018-2026

TABLE 91 Europe Market Value (US$ Mn), By Indication 2012-2017

TABLE 92 Europe Market Value (US$ Mn), By Indication 2018-2026

TABLE 93 Europe Market Value (US$ Mn), By Drug Type 2012-2017

TABLE 94 Europe Market Value (US$ Mn), By Drug Type 2018-2026

TABLE 95 Europe Market Value (US$ Mn), By Mode of Administration 2012-2017

TABLE 96 Europe Market Value (US$ Mn), By Mode of Administration 2018-2026

TABLE 97 Europe Market Value (US$ Mn), By Distribution Channel 2012-2017

TABLE 98 Europe Market Value (US$ Mn), By Distribution Channel 2018-2026

TABLE 99 Japan Market Value (US$ Mn), By Country 2012-2017

TABLE 100 Japan Market Value (US$ Mn), By Country 2018-2026

TABLE 101 Japan Market Value (US$ Mn), By Indication 2012-2017

TABLE 102 Japan Market Value (US$ Mn), By Indication 2018-2026

TABLE 103 Japan Market Value (US$ Mn), By Drug Type 2012-2017

TABLE 104 Japan Market Value (US$ Mn), By Drug Type 2018-2026

TABLE 105 Japan Market Value (US$ Mn), By Mode of Administration 2012-2017

TABLE 106 Japan Market Value (US$ Mn), By Mode of Administration 2018-2026

TABLE 107 Japan Market Value (US$ Mn), By Distribution Channel 2012-2017

TABLE 108 Japan Market Value (US$ Mn), By Distribution Channel 2018-2026

TABLE 109 APEJ Market Value (US$ Mn), By Country 2012-2017

TABLE 110 APEJ Market Value (US$ Mn), By Country 2018-2026

TABLE 111 APEJ Market Value (US$ Mn), By Indication 2012-2017

TABLE 112 APEJ Market Value (US$ Mn), By Indication 2018-2026

TABLE 113 APEJ Market Value (US$ Mn), By Drug Type 2012-2017

TABLE 114 APEJ Market Value (US$ Mn), By Drug Type 2018-2026

TABLE 115 APEJ Market Value (US$ Mn), By Mode of Administration 2012-2017

TABLE 116 APEJ Market Value (US$ Mn), By Mode of Administration 2018-2026

TABLE 117 APEJ Market Value (US$ Mn), By Distribution Channel 2012-2017

TABLE 118 APEJ Market Value (US$ Mn), By Distribution Channel 2018-2026

TABLE 119 MEA Market Value (US$ Mn), By Country 2012-2017

TABLE 120 MEA Market Value (US$ Mn), By Country 2018-2026

TABLE 121 MEA Market Value (US$ Mn), By Indication 2012-2017

TABLE 122 MEA Market Value (US$ Mn), By Indication 2018-2026

TABLE 123 MEA Market Value (US$ Mn), By Drug Type 2012-2017

TABLE 124 MEA Market Value (US$ Mn), By Drug Type 2018-2026

TABLE 125 MEA Market Value (US$ Mn), By Mode of Administration 2012-2017

TABLE 126 MEA Market Value (US$ Mn), By Mode of Administration 2018-2026

TABLE 127 MEA Market Value (US$ Mn), By Distribution Channel 2012-2017

TABLE 128 MEA Market Value (US$ Mn), By Distribution Channel 2018-2026

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

FIG. 1 Global Market Value (US$ Mn), 2012-2017

FIG. 2 Global Market Value (US$ Mn) Forecast, 2018-2026

FIG. 3 Global Market Value (US$ Mn) and Y-o-Y, 2017-2026

FIG. 4 Global Alzheimer’s Disease Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 5 Global Alzheimer’s Disease Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 6 Global Alzheimer’s Disease Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 7 Global Narcolepsy Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 8 Global Narcolepsy Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 9 Global Narcolepsy Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 10 Global Multiple Sclerosis Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 11 Global Multiple Sclerosis Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 12 Global Multiple Sclerosis Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 13 Global Amyotrophic Lateral Sclerosis Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 14 Global Amyotrophic Lateral Sclerosis Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 15 Global Amyotrophic Lateral Sclerosis Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 16 Global Other Indications Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 17 Global Other Indications Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 18 Global Other Indications Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 19 Global Biologics Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 20 Global Biologics Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 21 Global Biologics Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 22 Global Organic Compounds Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 23 Global Organic Compounds Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 24 Global Organic Compounds Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 25 Global Injectables Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 26 Global Injectables Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 27 Global Injectables Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 28 Global Oral Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 29 Global Oral Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 30 Global Oral Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 31 Global Others Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 32 Global Others Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 33 Global Others Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 34 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 35 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 36 Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 37 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 38 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 39 Global Retail Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 40 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 41 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 42 Global Online Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 43 North America Market Value (US$ Mn), By Country 2012-2017

FIG. 44 North America Market Value (US$ Mn), By Country 2018-2026

FIG. 45 North America Market Value (US$ Mn), By Indication 2012-2017

FIG. 46 North America Market Value (US$ Mn), By Indication 2018-2026

FIG. 47 North America Market Value (US$ Mn), By Drug Type 2012-2017

FIG. 48 North America Market Value (US$ Mn), By Drug Type 2018-2026

FIG. 49 North America Market Value (US$ Mn), By Mode of Administration 2012-2017

FIG. 50 North America Market Value (US$ Mn), By Mode of Administration 2018-2026

FIG. 51 North America Market Value (US$ Mn), By Distribution Channel 2012-2017

FIG. 52 North America Market Value (US$ Mn), By Distribution Channel 2018-2026

FIG. 53 Latin America Market Value (US$ Mn), By Country 2012-2017

FIG. 54 Latin America Market Value (US$ Mn), By Country 2018-2026

FIG. 55 Latin America Market Value (US$ Mn), By Indication 2012-2017

FIG. 56 Latin America Market Value (US$ Mn), By Indication 2018-2026

FIG. 57 Latin America Market Value (US$ Mn), By Drug Type 2012-2017

FIG. 58 Latin America Market Value (US$ Mn), By Drug Type 2018-2026

FIG. 59 Latin America Market Value (US$ Mn), By Mode of Administration 2012-2017

FIG. 60 Latin America Market Value (US$ Mn), By Mode of Administration 2018-2026

FIG. 61 Latin America Market Value (US$ Mn), By Distribution Channel 2012-2017

FIG. 62 Latin America Market Value (US$ Mn), By Distribution Channel 2018-2026

FIG. 63 Europe Market Value (US$ Mn), By Country 2012-2017

FIG. 64 Europe Market Value (US$ Mn), By Country 2018-2026

FIG. 65 Europe Market Value (US$ Mn), By Indication 2012-2017

FIG. 66 Europe Market Value (US$ Mn), By Indication 2018-2026

FIG. 67 Europe Market Value (US$ Mn), By Drug Type 2012-2017

FIG. 68 Europe Market Value (US$ Mn), By Drug Type 2018-2026

FIG. 69 Europe Market Value (US$ Mn), By Mode of Administration 2012-2017

FIG. 70 Europe Market Value (US$ Mn), By Mode of Administration 2018-2026

FIG. 71 Europe Market Value (US$ Mn), By Distribution Channel 2012-2017

FIG. 72 Europe Market Value (US$ Mn), By Distribution Channel 2018-2026

FIG. 73 Japan Market Value (US$ Mn), By Country 2012-2017

FIG. 74 Japan Market Value (US$ Mn), By Country 2018-2026

FIG. 75 Japan Market Value (US$ Mn), By Indication 2012-2017

FIG. 76 Japan Market Value (US$ Mn), By Indication 2018-2026

FIG. 77 Japan Market Value (US$ Mn), By Mode of Administration 2012-2017

FIG. 78 Japan Market Value (US$ Mn), By Drug Type 2018-2026

FIG. 79 Japan Market Value (US$ Mn), By Mode of Administration 2012-2017

FIG. 80 Japan Market Value (US$ Mn), By Mode of Administration 2018-2026

FIG. 81 Japan Market Value (US$ Mn), By Distribution Channel 2012-2017

FIG. 82 Japan Market Value (US$ Mn), By Distribution Channel 2018-2026

FIG. 83 APEJ Market Value (US$ Mn), By Country 2012-2017

FIG. 84 APEJ Market Value (US$ Mn), By Country 2018-2026

FIG. 85 APEJ Market Value (US$ Mn), By Indication 2012-2017

FIG. 86 APEJ Market Value (US$ Mn), By Indication 2018-2026

FIG. 87 APEJ Market Value (US$ Mn), By Drug Type 2012-2017

FIG. 88 APEJ Market Value (US$ Mn), By Drug Type 2018-2026

FIG. 89 APEJ Market Value (US$ Mn), By Mode of Administration 2012-2017

FIG. 90 APEJ Market Value (US$ Mn), By Mode of Administration 2018-2026

FIG. 91 APEJ Market Value (US$ Mn), By Distribution Channel 2012-2017

FIG. 92 APEJ Market Value (US$ Mn), By Distribution Channel 2018-2026

FIG. 93 MEA Market Value (US$ Mn), By Country 2012-2017

FIG. 94 MEA Market Value (US$ Mn), By Country 2018-2026

FIG. 95 MEA Market Value (US$ Mn), By Indication 2012-2017

FIG. 96 MEA Market Value (US$ Mn), By Indication 2018-2026

FIG. 97 MEA Market Value (US$ Mn), By Drug Type 2012-2017

FIG. 98 MEA Market Value (US$ Mn), By Drug Type 2018-2026

FIG. 99 MEA Market Value (US$ Mn), By Mode of Administration 2012-2017

FIG. 100 MEA Market Value (US$ Mn), By Mode of Administration 2018-2026

FIG. 101 MEA Market Value (US$ Mn), By Distribution Channel 2012-2017

FIG. 102 MEA Market Value (US$ Mn), By Distribution Channel 2018-2026

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Rare Neurological Disease Treatment Market